Invitrogen Launches Next-Generation Cell Culture Solution

Invitrogen Launches Next-Generation Cell Culture Solution for Immunology Research

New T-Cell Expansion Medium Provides Cost-efficient, T-Cell Doubling in a Serum-free Environm

Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced the launch of GIBCO® OpTmizer™ T-cell Expansion SFM, a next-generation solution for culturing and expanding human T-cells that does not require the addition of serum to achieve optimal, cost-efficient results. OpTmizer SFM will enable scientists to advance their research on the central role that T-cells play in human immune response. These cells are widely studied by scientists conducting basic and clinical research, as well as biotech and pharmaceutical companies and organizations studying biodefense.

Obtaining large amounts of viable cells for these studies is critical to this work, and led Invitrogen to specifically formulate OpTmizer SFM to enable superior cell growth and viability with consistent results, without the addition of serum. It achieves superior performance criteria for growth, viability and cell yield under serum-free conditions, compared to all other commercial T-cell media. This is an improvement over other products on the market for T-cell culture and expansion, which are limited in their performance without the addition of human serum to feed the cells – a process that adds cost, complexity and contamination risk.

OpTmizer SFM is also xeno-free, meaning that it does not contain material of non-human origin, which further enhances its safety, while decreasing variability of results from lot to lot. It is currently available in Research Use Only grade. This product is manufactured under cGMP regulations, and comes with an FDA Drug Master File to support regulatory filings. OpTmizer SFM expands Invitrogen’s portfolio of solutions for immunology research, which includes AIM V®, the only FDA 510(k) cleared commercial T-cell medium for human ex vivo tissue and cell culture processing applications, in addition to an extensive selection of serum- and xeno-free products.

Joydeep Goswami, Vice President of Invitrogen Primary and Stem Cell Systems, Life Technologies

"OpTmizer is the first commercially available xeno-free T-cell media that is capable of supporting large-scale expansion of T-cells in a completely serum-free manner. This will enable an easier transition for our customers from research to clinical applications due to fewer regulatory hurdles and processing steps in T-cell expansion, and will yield greater cost savings."

For more information, please visit: www.invitrogen.com and www.appliedbiosystems.com.

Additional Resources: Product Brochure

Scientific Paper: Expansion of Human Regulatory T-Cells from Patients With Type 1 Diabetes

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.